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Abstract
Background: Heat shock protein 70 (HSP70) protects inner ear cells from damage and death
induced by e.g. heat or toxins. Benzoquinone ansamycin antibiotic geldanamycin (GA) was
demonstrated to induce the expression of HSP70 in various animal cell types. The aim of our study
was to investigate whether GA induces HSP70 in the organ of Corti (OC), which contains the
auditory sensory cells, and whether GA can protect these cells from toxicity caused by a common
aminoglycoside antibiotic gentamicin.
Methods: To address these questions, we used the OC explants isolated from p3-p5 rats. As a
read-out, we used RT-PCR, ELISA and immunofluorescence.
Results: We found that GA at the concentration of 2 μM efficiently induced HSP70 expression on
mRNA and protein level in the OC explants. Confocal microscopy revealed that HSP70 induced
by GA is expressed by hair cells and interdental cells of spiral limbus. Preincubation of explants with
2 μM GA prior to adding gentamicin (500 μM) significantly reduced the loss of outer but not inner
hair cells, suggesting different mechanisms of otoprotection needed for these two cell types.
Conclusion: GA induced HSP70 in the auditory sensory cells and partially protected them from
toxicity of gentamicin. Understanding the molecular mechanisms of GA otoprotection may provide
insights for preventative therapy of the hearing loss caused by aminoglycoside antibiotics.
Background
Heat shock proteins (HSPs) are a group of highly con-
served proteins produced by all living organisms. HSPs
maintain cellular homeostasis and are involved in the
response to various stresses. The family of 70 kDa heat
shock proteins (HSP70) are ubiquitously expressed HSPs.
Under normal physiological circumstances, the constitu-
tively expressed HSP70 (70 kDa heat shock cognate pro-
tein, HSC70) functions as chaperone during protein
synthesis, intracellular transport and degradation. Under
stress conditions, such as hyperthermia, oxidative stress,
inflammation, exercise, exposure to toxins and ultraviolet
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light, starvation, hypoxia, or water deprivation, inducible
HSP70 (iHSP70, HSP72) provide cellular protection by
repairing the damaged proteins in cytoplasm and by
blocking apoptosis [1,2]. Consequently, the heat shock
proteins are also referred to as stress proteins and their up-
regulation is sometimes described more generally as a part
of stress response. The major stress-inducible isoform of
HSP70 is encoded by two genes - Hsp70-1 (Hspa1b) and
Hsp70-2  (Hspa1a) [3]. The expression of Hsp70-1  and
Hsp70-2 is regulated via transcription factor heat shock
factor 1 (HSF1). In cochlea, HSF1 is constitutively
expressed in hair cells, spiral ganglion cells and in the stria
vascularis [4,5]. Expressional induction of Hsp70 occurs in
the inner ear (cochlea) in response to hyperthermia [6],
transient ischemia [7], acoustic overstimulation [8] and
cisplatin [9]. The otoprotective role of HSPs in the cochlea
is well documented. Experiments with knock-out Hsf1-/-
and Hsp70-/- mice, demonstrated that the expression of
HSP70 is necessary to protect the cochlear hair cells from
noise exposure and aminoglycoside ototoxicity [10,11].
Heat shock and pharmaceuticals are two known
approaches of inducing HSP70 in vivo. Whole-body heat
stress or a local heat shock (perfusion of hot saline into
the middle ear cavity) substantially increased the expres-
sion of HSP70 in the cochlea and protected mice and
guinea pigs from acoustic injury [12,13].
In clinical settings, local induction of HSP70 by pharma-
ceuticals is more feasible than by a heat shock. One of
HSP70-inducing substances is geldanamycin (GA), a ben-
zoquinone ansamycin antibiotic and antitumor drug,
presently in clinical trials. GA binds to N-terminal ATP-
binding site of HSP90, resulting in activation of HSF
under non-stress condition [14]. GA has been shown to
induce HSP70 expression and to provide protection in a
number of mammalian cell types such as neurons, astro-
cytes and visual epithelial cells [15-18]. To date, however,
there is no report on the auditory system, in terms of a
protective effect of GA.
Gentamicin is an aminoglycoside antibiotic used to treat
many types of bacterial infections, particularly those
caused by Gram-negative bacteria. One of major side
effects of gentamicin is ototoxicity [19]. The ototoxicity of
gentamicin is attributed to the selective toxic effect on sen-
sory hair cells in cochlea and vestibular organ. Although
new generations of antibiotics have merged in the recent
decades, aminoglycosides are still being used in a variety
of medical conditions. Therefore, there are always consid-
erable interests in finding ways to prevent their ototoxic-
ity.
Our aim was to investigate whether GA induces the
expression of HSP70 in the explant cultures of the organ
of Corti (OC). Additionally, we wanted to test the ability
of GA to protect the outer and inner hair cells (OHCs/
IHCs) from ototoxicity caused by gentamicin.
Methods
Animals and dissection
Newborn Wistar rats (p3-p5) were used to prepare coch-
lear organotypic cultures. All studies were performed in
accordance with the German Prevention of Cruelty to Ani-
mals Act and were approved by the Berlin Senate Office
for Health (T0234/00).
The dissection procedure is similar to that described by
Sobkowicz et al. [20]. After decapitation, the heads were
cleaned with 70% ethanol and positioned with ventral
surface down. The scalp was removed and the skull was
transected along mid-sagittal plane. The brain was
scooped out to expose the posterior fossa. The temporal
bones were freed from the posterior hemi-skulls and
transferred into Petri dishes containing cold, sterile, buff-
ered saline glucose solution (BSG, glucose 11.4 mM).
Under a stereomicroscope (Stemi, SV6, Zeiss, Germany),
the tympanic membrane and annulus were laterally
peeled away and the surrounding cartilages were removed
exposing the cochlear capsule. The cochlear capsules were
bit off in small pieces from the oval window to the apex
or shucked off from the base integrally. The stria vascularis
and spiral ligament were stripped away as a single piece
from the base to the apex, and the OC was separated away
from the modiolus.
OC explant culture
The OC explants were incubated in 4-well culture dishes
(4 × 1.9 cm2, Nunc, Wiesbaden, Germany) containing
500 μl medium. For different further use, OC explants
were cultured in two different ways. For subsequent
reverse transcription polymerase chain reaction (RT-PCR)
and enzyme-linked immunosorbent assay (ELISA), whole
OC tissue was incubated free-floating in the medium. For
subsequent histological use, the OC was cut into three
parts consisting of apical, middle and basal turns, and
then the OC segments were positioned on the bottom of
dishes as a flat surface preparation and were held in place
by the surface tension of the culture medium. The culture
medium consisted of DMEM/F12 (1:1) (Gibco, Karlsruhe,
Germany) supplemented with 10% FBS (Biochrom AG,
Berlin, Germany), 0.6% glucose, 2 μl/ml insulin-transfer-
rin-Na-Selenit-Mix (Roche Diagnostics GmbH, Man-
nheim, Germany), 24 ng/ml recombinant human insulin-
like growth factor-I (rhIGF-I, R&D Systems, Wiesbaden-
Nordenstadt, Germany), and 100 U/ml penicillin (Grü-
nenthal GmbH, Aachen, Germany). The explants were
placed in an incubator (SANYO MCO-16AIC, 37°C, 5%
CO2) for 24 h to condition them before further treat-
ments.Journal of Biomedical Science 2009, 16:79 http://www.jbiomedsci.com/content/16/1/79
Page 3 of 12
(page number not for citation purposes)
GA and gentamicin treatment
GA (Cat. # Ant-g1, Invivogen, Toulouse, France) was dis-
solved in DMSO to make 1 mg/ml stock solutions. After
initial 24 h of culture, the medium was exchanged with
new medium containing a specific concentration of GA
(0.5, 1 or 2 μM) for up to 24 h. Then, OC explants were
fixed for staining or lysed for RNA isolation and protein
extraction.
Gentamicin sulfate (G1264, CAS # 1405-41-0, Sigma-
Aldrich, Munich, Germany) was dissolved in distilled
water to prepare 50 mM stock solution and diluted into
culture medium at final concentration of 500 μM. After
initial 24 h, OC explants were incubated in culture
medium containing 2 μM GA for 4 h and then exposed to
500 μM gentamicin for 24 h, or were treated simultane-
ously with GA and gentamicin for 24 h.
Total RNA samples were isolated from OC cultures using
the RNeasy Mini Kit (Qiagen GmbH, Hilden, Germany)
and on-column DNase digested with RNase-free DNase
Set (Qiagen GmbH, Hilden, Germany) according to the
manufacturer's instructions. The isolated RNA was quan-
tified spectrophotometrically with Ribogreen® RNA Quan-
titation Reagent (Molecular Probes, Göttingen, Germany)
and then stored at -80°C until needed.
cDNA preparation
First-strand cDNA was synthesized from 100 ng of total
RNA in a thermocycler (Perkin Elmer-applied biosystems
thermal cycler 9600, Foster City, USA). The RNA was
denatured by heating at 70°C for 5 min and quickly
cooled at 4°C. The reaction mixture contained 0.5 mM
dNTP Mix (Invitrogen GmbH, Karlsruhe, Germany), 3.8
μM Oligo(dT) (Biotez, Berlin, Germany), 26 U RNasin
(Promega Co., Madison, WI, USA) and 25 U MMLV
Reverse Transcriptase (Promega Co., Madison, WI, USA)
in a final volume of 20 μl of MMLV Reaction Buffer
(Promega Co., Madison, WI, USA). The RT reaction was
performed at 42°C for 60 min followed by enzyme inac-
tivation at 95°C for 5 min and cooling at 4°C. To exclude
cross-reaction of PCR primers with containing DNA in the
following PCR experiment, negative RT controls contain-
ing all reverse transcription components, including RNA
samples, were prepared by carrying out the reaction in the
absence of MMLV RT. In addition, another negative con-
trol containing nuclease-free water instead of RNA was set
up.
Real-time quantitative PCR
The Master Mix (containing FastStart Taq DNA Polymer-
ase, reaction buffer, SYBR Green I dye and MgCl2) for real-
time quantitative PCR (qPCR) was prepared from solu-
tion 1a (Enzyme) and solution 1b (Reaction Mix) (Light-
Cycler FastStart DNA Masterplus SYBR Green I, Roche
Dianostics GmbH, Penzberg, Germany) according to the
manufacturer's instructions. The PCR mixture contained 2
μl of cDNA, 10 pmol each reverse and forward specific
primers (BioTez, Berlin, Germany), 4 μl Master Mix and
PCR degree water in a final volume of 20 μl. A control PCR
reaction, which involved PCR master mix and the primers,
but no cDNA template, was used as a blank PCR reaction.
Housekeeping gene, encoding ribosomal protein S16
(rS16) was used as internal control. The sequence of prim-
ers used in this study was as follows: rS16 (forward GGG
TCC GCT GCA GTC CGT TC and reverse CGT GCG CGG
CTC GAT CAT CT); HSP70 (Hsp70-2) (forward 5'-ACC
AGG ACA CTG TTG AGT TC-3' and reverse 5'-ACT CAT
CTC CGA GTT CAC AC-3'). PCR was initiated by preincu-
bation at 95°C for 10 min followed by 35 cycles consist-
ing of denaturation at 95°C for 10 sec, annealing at 65-
70°C for 10 sec and extension at 72°C for 10-15 sec. Melt-
ing curves were obtained by final incubation from 60 to
95°C with a heating rate of 0.1°C/s and ended with cool-
ing down to 4°C in LightCycler System 2.0 (Roche Diag-
nostics, Basel, Switzerland).
To visualize amplicons, 2 μl of each PCR product was sep-
arated by electrophoresis on a 2-3% agarose gel (Gibco
BRL, Life Technologies, Paisley, Scotland) stained by Gel-
Star® Nuleic Acid Gel Stain (Cambrex Bio Science, Rock-
land, USA). The amplicons were visualized under
ultraviolet light using a Syngene-Gene Genius imaging
system (Synoptics Inc., USA), and the product size were
confirmed by comparison with DNA ladder Marker V
(Roche Diagnostics, Mannheim, Germany).
Threshold cycle (Ct) values acquired in real-time qPCR
were normalized to rS16 that served as an endogenous ref-
erence and calibrated to the control. Relative expression
level (fold change) of the target genes in each experimen-
tal sample was calculated using 2-ΔΔCt method [21], where
ΔCt = Ct (target gene) - Ct (reference gene) and ΔΔCt = ΔCt
(treated) - ΔCt (control).
ELISA
The ELISA kit, Human/Mouse/Rat Total HSP70 DuoSet®
IC (Cat. # DYC1663-5, R&D Systems, Wiesbaden-Nor-
denstadt, Germany), was used to quantify HSP70 protein
expression in OC explants. Free-floating OC explants were
lysed and the concentration of HSP70 protein in lysates
was measured according to the manufacturer's instruc-
tions. HSP70 concentration in OC lysates obtained from
ELISA was normalized to total protein concentration. Rel-
ative expression level of HSP70 in each experimental sam-
ple was calculated as picogram of HSP70 per 1 μg of total
protein. Six OCs were used per each time point.Journal of Biomedical Science 2009, 16:79 http://www.jbiomedsci.com/content/16/1/79
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Immunofluorescence
HSP70 staining
OC explants were fixed in 4% paraformaldehyde in 0.1 M
phosphate-buffered solution (PBS) at room temperature
for 30 min. Next, the fragments were washed two times
with PBS and permeabilized with 0.2% Triton X-100 in
PBS for 30 min. After two washes in PBS, the fragments
were incubated in blocking solution (0.8% goat serum,
0.4% Triton and 2% bovine serum albumin in PBS) at
room temperature for 3 h and then incubated overnight at
4°C with mouse anti-HSP70 monoclonal antibody (Cat.
# SPA-810, Stressgen Bioreagents, Ann Arbor, USA)
(1:200 dilution in blocking solution, 5 μg/ml). In the neg-
ative control samples, mouse anti-HSP70 monoclonal
antibody was substituted with an isotype control (mouse
IgG1, Dianova, Hamburg, Germany) (1:40 dilution in
blocking, 5 μg/ml). The fragments were washed three
times in PBS, incubated for 3 h at room temperature with
goat anti-mouse IgG conjugated with fluorescence isothi-
ocyanate (FITC) (Dianova, Hamburg, Germany) (1:200
dilution in blocking solution, 7.5 μg/ml) and washed
three times in PBS. The fragments were mounted on glass
slides in Prolong Gold® antifade reagent (P36930, Molec-
ular Probes (Invitrogen, Karlsruhe, Germany) and exam-
ined using a confocal microscope (Leica TCS SPE, Wetzlar,
Germany).
Hair cell quantification
OC explants were fixed for 30 min in 4% paraformalde-
hyde in 0.1 M PBS at room temperature. Then, the frag-
ments were washed two times with PBS and
permeabilized with 0.2% Triton X-100 in PBS for 30 min.
The fragments were washed two times with PBS and incu-
bated with 5 μg/ml solution of phalloidin conjugated
with tetramethyl rhodamine isothiocyanate (TRITC)
(P1951, Sigma-Aldrich, Munich, Germany) at room tem-
perature for 30 min. After washes with PBS, the fragments
were mounted with mounting medium containing 1,4-
diazabicyclo[2.2.2]octane (DABCO) (D2522, Sigma-
Aldrich, Munich, Germany).
The OC fragments were examined under a fluorescence
microscope (Leica DMIL, Wetzlar, Germany) with filters
appropriate for TRITC (excitation: 544 nm, emission: 572
nm). There are three rows of OHCs and one row of IHCs
along the whole OC. The hair cell numbers were counted
over a longitudinal distance of 100 μm in five separated
regions of each cochlear part (magnification 400×). Cells
were considered missing when there was a gap in the nor-
mal arrays and no stereocilia or cuticular plates were to be
seen. A mean value was calculated for each explant and at
least four explants were used for each experimental condi-
tion. The fragments were photographed with a digital
camera (Canon PowerShot S40). The contrast and bright-
ness of images were adjusted by using Adobe Photoshop
(version 9.0) software.
Statistical analyses
Means ± standard errors of the mean (SEM) were calcu-
lated for all parameters measured. The effect of GA on hair
cell viability, HSP70 induction or gentamicin-induced
hair cell loss were tested by two-way analysis of variance
(ANOVA) followed by Scheffé's post-hoc test. To analyze
the effect of GA on gentamicin-induced hair cell loss, the
codes of the grouping variable (controls, gentamicin, GA
before gentamicin, and GA and gentamicin simultane-
ously) were selected altogether and in pairs. A p-value of
less than 0.05 was considered statistically significant. All
statistical test and graphics were made using the software
package Statistica 7.1 (StatSoft).
Results
The effect of geldanamycin on hair cells
To determine if GA is safe for use in OC explant cultures
and has no cytotoxic effects on hair cells, we treated OC
explants for 24 h with GA at varying concentration, which
we chose based on the literature [16,18]. Next, using phal-
loidin staining and hair cell counting, we determined the
viability of hair cells. Figure 1 shows the scores of inner
and outer hair cells in the OC explants treated with 0.5, 1
and 2 μM GA versus untreated explants (control). We have
found that GA does not affect the numbers of IHCs (Fig.
1A) and OHCs (Fig. 1B) in apical, middle or basal part of
OC, as compared to the untreated controls (two-way
ANOVA). The epifluorescence micrographs in Figure 2
show OC explants treated with 2 μM GA for 24 h and then
stained with phalloidin-TRITC to label the actin fila-
ments. Three orderly rows of OHCs and one row of IHCs
were seen, and the morphology of hair cells was not
affected.
Taken together, these results suggest that GA at the con-
centration between 0.5 μM and 2 μM is not toxic to hair
cells in the OC explants. For all further experiments, we
have chosen the GA concentration of 2 μM.
Geldanamycin induces HSP70 production in the OC 
explants
To determine whether GA induces HSP70 expression in
OC and to find out its cellular localization, we treated the
explant cultures with 2 μM GA for 24 h and quantified
HSP70 expression at mRNA and protein levels by RT-PCR
and ELISA, respectively.
First, we investigated the time course of HSP70 mRNA
expression in OC explants induced by GA. Two-way
ANOVA indicated significant differences in the HSP70
mRNA expression between GA-treated groups and con-
trols (p < 0.00001) as well as during different times afterJournal of Biomedical Science 2009, 16:79 http://www.jbiomedsci.com/content/16/1/79
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induction (p < 0.01). Post-hoc analysis (Scheffé test)
revealed, that induction of HSP70 mRNA (Fig. 3A)
became significant after 4 h of GA treatment (average 9.9-
fold increase against untreated control, SEM = 1.5) and 8
h of treatment (average 9.4-fold increase against control,
SEM = 1.5).
Second, we performed ELISA with the GA-treated and
untreated OC explant lysates. Two-way ANOVA demon-
strated significant differences in the HSP70 concentration
between GA-treated groups and controls (p < 0.001) as
well as between different times (p < 0.01). Post-hoc anal-
ysis (Scheffé test) revealed, that after 8 h of treatment with
GA, the concentration of HSP70 rose significantly (Fig.
3B) and reached 462 pg of HSP70/μg of total protein
(SEM = 126 pg/μg) as compared to the untreated control
(36 pg of HSP70/μg of total protein, SEM = 8 pg/μg).
The concentration of HSP70 relative to total protein con-
centration in GA-treated explants was normalized to the
corresponding controls and presented as a fold change
together with the mRNA ratio (Fig 3C). The induction of
HSP70 on protein level followed the induction on mRNA
level with a 2 h delay (p < 0.05, interaction effect, two-way
ANOVA).
To localize the HSP70 protein induced by GA in the OC
explants, we treated OC explants with 2 μM GA for 8 h
(the time point where HSP70 protein expression was
highest), fixed and stained the specimens with anti-
HSP70 monoclonal antibody. In the untreated OC
Geldanamycin does not cause hair cell loss Figure 1
Geldanamycin does not cause hair cell loss. Number of 
hair cells per 100 μm length of the apical, middle and basal 
parts of the OC explants from controls and GA-treated sam-
ples. (A) IHCs; (B) OHCs. Shown are means ± SEM (control 
and 2 μM GA: n = 6; 0.5 and 1 μM GA: n = 4).
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Geldanamycin does not cause morphological changes in hair  cells Figure 2
Geldanamycin does not cause morphological changes 
in hair cells. Shown are representative epifluorescence 
micrographs of phalloidin-TRITC-labeled hair cells in OC cul-
tures treated with 2 μM GA for 24 h.
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explants, we observed some HSP70 immunoreactivity in
spiral limbus (Fig. 4A), in particular in the fibroblasts (Fig.
4B) and to lesser extend in the interdental cells (Fig. 4C).
After 8 h of treatment with GA, OC explants were strongly
HSP70-positive (Fig. 5A), in particular OHCs and IHCs
(Fig. 5B) and limbal interdental cells (Fig. 5C). There was
no HSP70 immunoreactivity in the OC explants where
addition of primary anti-HSP70-antibody was substituted
with an isotype control.
Effect of Geldanamycin on gentamicin-induced hair cell 
loss
Exposure to gentamicin for 24 h led to a severe loss of
OHCs in the apical, middle and basal parts of OC
explants, as compared to untreated controls (Fig. 6). The
stereocilia bundles were missing on most of remaining
OHCs.
To study the influence of GA on gentamicin-induced tox-
icity, we subjected the OC explants to one of the following
treatment protocols:
A) 4 h pretreatment with GA (2 μM) prior to 24 h gen-
tamicin treatment (500 μM),
B) simultaneous treatment with GA (2 μM) and gen-
tamicin (500 μM) for 24 h, followed by staining with
phalloidin-TRITC to visualize hair cells and scoring
under fluorescence microscope.
In the OC explants pretreated with GA prior to addition of
gentamicin, the loss of OHC was reduced in apical and
middle parts of OC, compared to the OHC loss in
explants treated with gentamicin alone (Fig. 6). Hair cell
scores confirmed this observation. Gentamicin induced a
loss of 28%, 47% and 54% of OHCs in the apical, middle
and basal part, respectively. Pretreatment of the OC
explants with GA significantly reduced this damage (p <
0.00001, two-way ANOVA). Post-hoc analysis (Scheffé
test) confirmed that the number of surviving OHCs was
higher in the GA-pretreated apical part (39.3 ± 0.8) than
in gentamicin-treated only (31.9 ± 1.0), p < 0.001. Simi-
larly, in the middle part, pretreatment with GA increased
the number of surviving OHC (31.5 ± 0.8) as compared to
gentamicin alone (23.1 ± 0.8), p < 0.0001 (Fig. 7B). How-
ever, there was no statistically significant effect of GA pre-
treatment in the highly damaged basal part of OC.
In the OC explants that were simultaneously treated with
GA and gentamicin, the OHC loss in the whole OC was
also significantly lower than with gentamicin alone (p <
0.0001, two-way ANOVA). However, the post-hoc test
indicated protective effect of GA on OHCs only in the
middle cochlear part (p < 0.05). The number of surviving
OHCs was 28.6 ± 1.3 in the GA-gentamicin-treated group
and 23.1 ± 0.8 in gentamicin treatment alone. These
results suggest that the pretreatment of OC explants with
GA significantly inhibited loss of OHCs caused by gen-
tamicin.
Gentamicin produced not only a loss of OHCs but also of
IHCs (p < 0.001 vs. controls). Surprisingly, we did not
Geldanamycin induces HSP70 mRNA and protein production  in the OC explants Figure 3
Geldanamycin induces HSP70 mRNA and protein 
production in the OC explants. Time course of HSP70 
mRNA and protein expression in OC explants during 2 μM 
GA treatment. (A) Time course of HSP70 mRNA relative 
expression (n = 7 each). (B) Time course of HSP70 protein 
expression (relative to total protein) (n = 6 each). (C) Com-
parison of time course of HSP70 mRNA and protein expres-
sion (fold changes). Shown are means ± SEM. */**p < 0.01/
0.001 vs. controls.
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observe significant protective effect of GA on gentamicin-
induced IHC loss (Fig. 7A).
Discussion
The inner ear is subjected to various types of stress such as
aging, acoustic trauma and ototoxic drugs, which can
result in cell damage and/or death. Sensory hair cells are
extremely susceptible to injury. In contrast to lower spe-
cies (fish, bird, etc.), mammals cannot regenerate hair
cells [22]. Hair cell loss results in an acquired permanent
hearing loss that, to date is incurable [23]. Therefore, hair
cells are an important target for protective interventions.
One of the substances protecting some cells from death is
GA [17]. The implicated mechanism of protection is via
induction of HSP70 synthesis. In present work, we found
that GA induces production of HSP70 on the mRNA and
protein level and that HSP70 localizes to the hair cells. We
have also unequivocally demonstrated that the pretreat-
ment with GA protects the OHCs but not IHCs in apical
and middle parts of OC explants from gentamicin toxic-
ity.
Because of the very high sensitivity of the cochlea to oto-
toxic substances (especially the basal turn), we first tested
GA for its possible toxic properties in this study. Although
GA was shown to be toxic to some cells, even at a relative
low concentration (0.1 μg/ml or 0.18 μM) [24], in the
present study treatment of OC explants for 24 h with 2 μM
GA did not cause hair cell damage. Next, we demonstrated
that GA up-regulates the expression of HSP70 in OC
explants, on the transcriptional and translational levels.
The up-regulation of HSP70 mRNA preceded that of
HSP70 protein, which suggests that the up-regulation of
HSP70 took place on transcriptional level and the increase
of HSP70 protein was a secondary process. HSP70 protein
expression in OC began within 4 h of treatment with GA
and persisted at relative high level until 24 h, corroborat-
ing temporal expression pattern seen in previous studies
with hippocampal cell line [25] and visual sensory cells
[18].
Fluorescence microscopy indicated that GA induced
HSP70 mainly in OHCs, IHCs and in interdental cells of
spiral limbus, but not in spiral ganglion cell bodies or
nerve fibers. This localization pattern of HSP70 protein is
similar to that of HSF1 reported by Fairfield et al. [5],
In the untreated OC explants, HSP70 localizes to limbal fibrocytes and interdental cells Figure 4
In the untreated OC explants, HSP70 localizes to limbal fibrocytes and interdental cells. Shown are the repre-
sentative laser confocal micrographs of untreated OC cultures stained with a monoclonal antibody against HSP70 followed by 
FITC-conjugated secondary antibody. (A) the entire explant (basal part); (B) HSP70-positive fibrocytes in spiral limbus; (C) 
interdental limbal cells.
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except for the negative expression in spiral ganglion. It is
also consistent with that of HSP70 mRNA induced by heat
shock [26]. However, our results are in contrast to another
report showing that HSP70 protein induced by heat shock
was present in all cochlear structures except OC [6]. This
inconsistency may be due to different stimuli (heat vs.
GA) or, even more likely, due to different experimental
models used (animal vs. OC explant).
To damage the hair cells, we used gentamicin and
observed more severe hair cell damage in basal part than
in apical or middle parts, consistent with previous in vitro
studies in mice and rat OC explants [27,28]. The question
"why  is gentamicin ototoxic?" was asked by many
researches, but it remains open. The major proposed oto-
toxic mechanism is generation of free radicals. Overpro-
duction of reactive oxygen species and the resulting red-ox
imbalance have been demonstrated to be the important
mechanism of gentamicin ototoxicity. Priuska and Sch-
acht have found that gentamicin was able to accelerate the
formation of free radicals in the presence of iron salts [29].
There is increasing evidence that hair cells damaged by
gentamicin die by an active cell death - apoptosis. Gen-
tamicin treatment has been shown to result in chromatin
condensation and DNA fragmentation, hallmarkers of
apoptosis [30,31]. Moreover, cytochrome c release from
the mitochondria into the cytoplasm and activation of
caspase-8, caspase-9 and caspase-3 were observed in gen-
tamicin-damaged hair cells, suggesting that auditory hair
cell death is a result of gentamicin exposure in a caspase-
dependent pathway [31,32]. In addition to caspase-medi-
ated apoptosis, the c-Jun N-terminal kinase (JNK) apop-
totic pathway was also implicated in gentamicin
ototoxicity. It was demonstrated that gentamicin activated
JNK-dependent apoptotic pathway in IHCs in vivo [33].
Interestingly, the most recent research from the laboratory
of Sha demonstrated that in the OC explants isolated from
mice, gentamicin induces histone deacetylation and in
this way induces cell death [34]. Gentamicin was reported
to induce de novo production of HSP70 in the renal cell
line [35]. However, the synthesis pick of HSP70 was
observed relatively late after administration of gentamicin
(72 h), in which time the damage to the cochlear hair cells
is very extensive, and was related to by authors as a marker
of renal injury.
We found that GA partially attenuates gentamicin-
induced hair cell loss. The most tempting interpretation
Geldanamycin-induced HSP70 localizes to hair cells and interdental cells Figure 5
Geldanamycin-induced HSP70 localizes to hair cells and interdental cells. Shown are the representative laser confo-
cal micrographs of GA-treated OC cultures stained with a monoclonal antibody against HSP70 followed by FITC-conjugated 
secondary antibody. (A) the entire explant (basal part); (B) HSP70-positive IHCs and OHCs; (C) HSP70-positive interdental 
cells.
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on this finding is that the protective effect of GA against
gentamicin-induced hair cell loss is the consequent cyto-
protective action of HSP70 induced by GA. Harrison et al.
proposed a pathway of GA-mediated neuroprotection
based on their findings, that GA exerts protection by
destabilization of the Hsp90-HSF1 complex, nuclear
translocation of HSF1, activation of the Hsp70 promoter
and transcriptional up-regulation of HSP70 [36]. Protec-
tive effects of HSP70 are attributed to its critical function
as a molecular chaperone. This function involves refold-
ing of misfolded and thus toxic proteins in cytoplasm and
reducing protein aggregation. Furthermore, previous stud-
ies have demonstrated that HSP70 inhibits apoptosis in a
variety of systems by interfering with various apoptotic-
signaling cascades that were indicated to be involved in
mechanism of ototoxicity. HSP70 was shown to strongly
inhibit JNK activation [37] and to reduce mitochondrial
cytochrome c release to cytosol [38]. In addition, HSP70
prevented the recruitment of pro-caspase-9 to the apopto-
some complex, thus blocking the assembly of a functional
apoptosome and consequent activation of caspase-9 [1].
Lastly, HSP70 was suggested to inhibit processing of cas-
pase-3 [37] and to inhibit cell death even after caspase-3
has been activated [39].
We observed the protective effect of GA in apical and mid-
dle parts of OC explants exposed to gentamicin pretreated
with GA for 4 h. At that time, HSP70 mRNA had reached
significantly high level in the OC explants, followed by
protein production. However, when OC explants were
concurrently treated with gentamicin and GA, the protec-
tive effect of GA was small and targeted only to the middle
part of OC. These results are at present encouraging for the
protection but not for the treatment of gentamicin-
induced ototoxicity. It has already been demonstrated
that GA provided post-exposure neuroprotection in HT22
hippocampal cell line against glutamate-induced oxida-
tive toxicity [25]. This encourages further investigations in
order to define the therapeutic window for GA.
Even though HSP70 expression was induced by GA in
both OHCs and IHCs, and despite the fact that OHCs and
Geldanamycin protects hair cells against gentamicin-induced toxicity Figure 6
Geldanamycin protects hair cells against gentamicin-induced toxicity. Representative epifluorescence micrographs 
of phalloidin-TRITC-labeled hair cells in untreated OC explants (negative control), treated with gentamicin (500 μM) for 24 h 
or pretreated with GA for 4 h prior to gentamicin exposure.
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IHCs appeared to be equally susceptible to gentamicin,
only OHCs were protected by GA. These results suggest
that the mechanism of OHC and IHC loss may differ
between these two cell types and that in the OHCs but not
in IHCs, the ototoxic effect of gentamicin may be inhib-
ited by GA-induced HSP70. It is also possible that other
than HSP70 targets of GA mediate the protection. For
instance, GA not only increased the expression of HSP70
but also the expression of HSP90 and HSP27 in COS-1
cells [40] and renal cells [36]. HSP90 and HSP27 have
been shown to suppress the aggregation of various pro-
teins and facilitate degrading unwanted and/or harmful
proteins, hence act as general protective chaperones
[41,42]. They also can inhibit apoptosis by preventing the
assembly of apoptosome [42,43]. It has been demon-
strated that HSP90 and HSP27 were induced in IHCs by
heat shock [10,13]. It is unknown whether HSP90 and
HSP27 were induced by GA in the present study, which
will be determined in further investigations.
Nevertheless, based on the present results, the protective
effect of GA against ototoxic hair cell death may be attrib-
uted to the actions of HSP70 induced by GA. Further
investigations are needed to reveal the exact molecular
mechanisms underlying the otoprotective role of GA,
which may provide insights for therapeutic approaches
aimed at preventing hair cell damage induced by various
ototoxic agents, or even other deleterious stresses.
The administration of GA in clinical settings is limited due
to its high hepatotoxicity [24]. In addition, GA has shown
to be incapable of crossing the blood brain barrier [44],
which is very similar to blood labyrinth barrier [45]. These
disadvantages led to the development of GA analogues.
17-Allylamino-17-demethoxygeldanamycin (17-AAG) is
an analogue chemically derived from GA. 17-AAG is con-
sidered less hepatotoxic and more stable than GA and has
been shown to cross the blood brain barrier [46]. It is cur-
rently in early stage clinical trials as a chemotherapeutic
agent [47]. Another analogue, 17-Dimethylaminoethyl-
amino-17-demethoxygeldanamycin (17-DMAG) is more
water-soluble than 17-AAG and has excellent bioavailabil-
ity, thus is more practicable in preclinical models [48]. 17-
AAG and 17-DMAG have been indicated to induce HSP70
in a variety of cells and provided some corresponding pro-
tective effects [36,48-50]. Although there is no evidence so
far supporting otoprotective effect of these two GA ana-
logues, 17-AAG and 17-DMAG may be supposed to have
protective roles in inner ear, which would be validated in
future studies.
Conclusion
In conclusion, we show for the first time that GA induces
transcription and translation of HSP70 in the OC
explants. In addition, we demonstrate the protective effect
A) Geldanamycin has no effect on IHC survival during the  gentamicin-induced ototoxicity Figure 7
A) Geldanamycin has no effect on IHC survival dur-
ing the gentamicin-induced ototoxicity. Number of 
IHCs per 100 μm length of the apical, middle and basal parts 
of the OC explants counted in (1) controls (n = 6), (2) gen-
tamicin-treated (500 μM) samples (GM, n = 15), (3) 4 h of 
GA (2 μM) pretreatment prior to 24 h of gentamicin (500 
μM) treatment (GA-pre + GM, n = 8), and (4) concurrent 
treatment with GA (2 μM) and gentamicin (500 μM) for 24 h 
(GA + GM parallel, n = 9). Shown are the means ± SEM. B) 
Geldanamycin protects OHC in apical and middle 
OC parts from the gentamicin-induced ototoxicity. 
Number of OHCs per 100 μm length of the apical, middle 
and basal parts of the OC explants counted in: (1) controls 
(n = 6), (2) gentamicin-treated (500 μM) samples (GM, n = 
15), (3) 4 h of GA (2 μM) pretreatment prior to 24 h of gen-
tamicin (500 μM) treatment (GA-pre + GM, n = 8), and (4) 
concurrent treatment with GA (2 μM) and gentamicin (500 
μM) for 24 h (GA + GM parallel, n = 9). Shown are the 
means ± SEM. */**/***p < 0.05/0.01/0.001 vs. gentamicin-
treated samples.
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of GA against gentamicin ototoxicity in the OHCs but not
the IHCs. GA may provide insights for therapeutic
approaches aimed at preventing and ameliorating the
extent of acquired hearing loss.
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